Localized Tenosynovial Giant Cell Tumors and Indicators of Surgical Recurrence Authors: Lawrence C Hurst, Alexander B Dagum, Samantha I Muhlrad, Anne M Meo, Edward D Wang, David E Komatsu Published: 2026 ABSTRACT AbstractPurposeLocalized tenosynovial giant cell tumors (GCTTS), also known as giant cell tumors of tendon sheath, are benign lesions that represent the second most common tumor of the hand. The standard treatment for GCTTS is marginal excision; however, recurrence is common, with rates of 4% to 56% reported in the literature. This study aimed to identify clinical, imaging, and surgical factors associated with recurrence following surgical excision of localized GCTTS.MethodsIn this retrospective cohort study, following institutional review board approval, we analyzed 74 patients with histologically confirmed localized GCTTS treated at a single academic medical center between 2001 and 2024. The mean follow-up was 7.4 years. All surgeries were performed by fellowship-trained hand surgeons using marginal excision with surgical adjuncts including extensile incisions, loupe magnification, tourniquet control, and secondary survey of the surgical bed. Patients were divided into nonrecurrent (n = 63) and recurrent (n = 11) cohorts. Fifty-five clinical parameters were collected from medical records and patient interviews. Statistical analyses were performed using Fisher exact tests to compare clinical parameters between the nonrecurrent and recurrent cohorts.ResultsThe overall recurrence rate was 15% with a mean follow-up of 7.4 years. Three statistically significant predictors of recurrence were identified: (1) Bone involvement was present in 100% of recurrent cases versus 47.6% of nonrecurrent cases, representing the strongest predictor. Although bone involvement demonstrated high sensitivity (100%), it had low specificity (52.4%). (2) Neurovascular bundle involvement (63.6% vs 25.4%) and (3) presence of satellite lesions (18.2% vs. 0%) were also identified; however, this last finding is based on only two cases and should be interpreted with caution as a preliminary observation rather than a confirmed predictor. Joint involvement (81.8% vs 58.7%) and flexor tendon involvement (45.5% vs 23.8%) demonstrated trends toward recurrence without reaching statistical significance. Tumor size, duration of symptoms, pseudocapsule integrity, surgeon’s experience, and osteoarthritis were not associated with recurrence. The wide confidence intervals reflect the limited precision inherent in the small sample size.ConclusionsBone involvement and neurovascular bundle involvement are significant predictors of recurrence in localized GCTTS. The exclusive occurrence of satellite lesions in the recurrent group suggests greater vigilance for satellite lesions during surgery; however, the sample is insufficient to establish a definitive predictive relationship. The relatively low recurrence rate (15%) achieved in this series likely reflects the standardized surgical approach with meticulous technique. Notably, the high nonrecurrence rate (73.2%) among patients with bone involvement suggests that aggressive curettage as part of a standardized protocol can substantially mitigate recurrence risk even in these technically challenging cases. Preoperative magnetic resonance imaging is valuable for identifying these high-risk features and guiding surgical planning. Until additional prognostic markers become available, meticulous surgical technique with attention to identified risk factors remains the cornerstone of preventing recurrence in localized tenosynovial giant cell tumors. Patients with these high-risk factors of recurrence should also be counseled about recurrence and followed at least 5 years.Type of study/level of evidencePrognostic III.Key words: Bone involvement, Giant cell tumor of tendon sheath, Neurovascular bundle, Satellite lesions, Surgical recurrence Giant cell tumor of tendon sheath (GCTTS) is classified by the World Health Organization (WHO) as a localized tenosynovial giant cell tumor. This tumor was first described by Chassaignac in 1852 as a fibrous xanthoma.1 Although this tumor has been described under numerous historical names, the 2020 WHO Classification of Soft Tissue and Bone Tumours now uses the term tenosynovial giant cell tumor (TGCT), with localized and diffuse subtypes.2, 3, 4 GCTTS is the second most common tumor of the hand after ganglion cysts, but this lesion remains rare, with an incidence of 11 cases per million with 9.2 per million in localized GCTTS and 1.8 per million in diffuse GCTTS.2,3,5, 6, 7, 8, 9 More common in women, GCTTS is slow growing with a reported duration at presentation ranging from 2 weeks to 30 years.6,10, 11, 12, 13 The average age at presentation is 43.3 years (range 3 to 82 years).5,6,11,13, 14, 15 GCTTS commonly involves the radial digits.8,15 The most frequently involved sites are the distal interphalangeal joint (DIP) joint and the volar proximal phalanx, with 10% involving the neurovascular bundles.5,8,12,15, 16, 17 These tumors rarely involve the palm and the presence of more than one in the same hand is rare.7,8 However, small satellite lesions can be associated with a single localized GCTTS.5,7,10,16,18 Typically, patients present with a slow growing painless mass. GCTTS may enlarge but cannot fluctuate in size like a ganglion. A history of trauma is reported in approximately 10% of cases. Some pain complaints may be secondary to osteoarthritis nearby joints, whereas some patients report pain associated with the tumor.2,5,16,19 On physical examination, GCTTS is typically smooth, possibly multinodular, immobile, nonfluctuant lesions. GCTTS can change the color of the overlying skin. Unlike ganglion cysts, localized tenosynovial giant cell tumors rarely transilluminate with light.10,12,15,20 The size averages 1.5 cm (range 0.5 to 11 cm in diameter).8,12,15,16,20 Joint range of motion may be decreased because of the mass effect of the GCTTS, intra-articular extensions of the lesion, or coexisting arthritis.20 Approximately, 10% of GCTTS involve the digital neurovascular bundle, resulting in potential decreased sensation and a positive Tinel’s sign.10,15 Typically, GCTTS is nontender, but one study reported tenderness in 31% of cases.21 Routine imaging studies, including x-ray, ultrasound, and magnetic resonance imaging (MRI) can be used to define and characterize GCTTS.10,12,14, 15, 16,20,22, 23, 24 There is no effective nonsurgical treatment for this tumor.10 The primary treatment for GCTTS is a complete open excision. However, a true en bloc excision is often not practical for these aggressive but benign tumors. To preserve function, the current standard of care is a marginal excision of this nonmetastasizing tumor.5,15 Recent international consensus guidelines recommend a multidisciplinary approach to TGCT management, with surgical resection remaining the standard of care for symptomatic localized disease.4,22 Using this approach the average reported rate of recurrence has varied widely from as low as 4% to as high as 56%.5,10,11,15,18,20,25,26 More recent series report recurrence rates of 7% to 44%, with positive surgical margins increasingly recognized as the strongest predictor of recurrence.11,14,27 A review by Lanzinger and Bindra26 found an average recurrence rate of 28.5% for 17 studies. Despite numerous studies examining GCTTS recurrence, few have combined a large sample size with extended follow-up to evaluate predictors of recurrence following standardized surgical treatment by fellowship-trained hand surgeons. We therefore performed a retrospective cohort study of 74 patients with localized GCTTS treated at our institution with a mean follow-up exceeding 7 years to determine whether bone involvement, neurovascular bundle involvement, and satellite lesions remain robust indicators of recurrence when treated with a standardized meticulous surgical protocol. Materials and Methods Approval from our institutional review board was obtained for this retrospective cohort study. Inclusion criteria were all patients diagnosed with a biopsy consistent with a GCTTS following surgical excision between 2001 and 2024 with minimum of 1 year follow-up. These marginal excisions included extensile incisions, magnification, tourniquet use, pseudocapsule preservation, collateral ligament excision, arthrotomy or fusion, grafting of invaded skin, flexor and/or extensor exploration, identification of satellite lesions, neurovascular bundle debridement, and secondary survey of the surgical bed. All surgeries were performed by hand fellowship-trained and certified hand surgeons working at our university hospital. Between 2001 and 2024, 88 surgeries were performed with lesions diagnosed by a pathologist as localized GCTTS. Sixteen cases were excluded because of inadequate follow-up of less than 1 year. Therefore, 74 cases were analyzed with 63 patients in the nonrecurrent cohort and 11 patients in the recurrent cohort (Fig. 1). For each of the patients, 55 clinical parameters were collected from archived article records, electronic medical records, and phone consultations. Flow chart for study enrollment. A total of 88 giant cell tumors of tendon sheath were initially identified. After screening from inclusion criteria, 74 cases were included in the analysis and were divided into nonrecurrent and recurrent cohorts of 63 and 11 cases, respectively. Data were averaged for the recurrent and nonrecurrent cohorts and reported as total numbers, percentages, averages, and ranges, as appropriate. Statistical analyses were performed to compare characteristics between recurrent and nonrecurrent cohorts using Fisher exact tests, independent samples t tests, or Welch’s t tests, as appropriate, and P values less than .05 were considered significant. Odds ratios (ORs) were calculated for each variable with corresponding 95% confidence intervals (95% CIs) using the Woolf logit method. For variables with zero-cell counts (bone involvement, satellite lesions), the Haldane–Anscombe correction (addition of 0.5 to each cell) was applied before calculating ORs and confidence intervals.28,29 The 55 clinical parameters were evaluated against only 11 recurrence events, yielding an events per variable (EPV) ratio of 0.2, which is well below the commonly recommended minimum of 10. This low EPV increases the risk of overfitting and type I error. However, each parameter was evaluated individually using univariate Fisher exact tests to mitigate overfitting concerns. Results Patient demographics (sex was based on self-report and age was based on time of surgery) and symptom duration are summarized in Table 1. The recurrent group had a higher proportion of females (82% vs 67%, P = .49). Most patients were right-handed with various occupations. Table 1Patient Demographics and Symptom DurationCharacteristicOverall (n = 74)Nonrecurrent (n = 63)Recurrent (n = 11)P ValueSex (F:M)51:2342:219:2.48∗F (%)69%67%82%.48∗Average age (y)50 (16–83)49 (16–83)52 (29–80).36†Average duration (mo)17 (1–144)13.4 (0.75–120)25 (2–144).326‡∗Fisher exact test.†Independent samples t test.‡Welch’s t test. Patient Demographics and Symptom Duration Fisher exact test. Independent samples t test. Welch’s t test. Follow-up data are presented in Table 2. The overall recurrence rate was 15%, with an average interval of 3 years. The GCTTS occurred in the right hand in 60% of the patients, with the radial digits more frequently involved. The dorsum of the digit was involved in 59% and palmar in 41%. The primary symptom was an enlarging mass with mild pain in 66%. Numbness or limited motion were uncommon and did not differ between the nonrecurrent and recurrent cohorts. Table 2Follow-Up DurationMeasureAverage (y)Range (y)Overall follow-up (n = 74)7.41.00–23Nonrecurrent group (n = 63)7.91.10–23.1Recurrent group (n = 11)4.21.00–13.4Interval from first to second surgery3.00.33–12 Follow-Up Duration GCTTS were evaluated using x-ray, ultrasound, MRI, and histology. Of note, x-rays were frequently performed, in 90% of nonrecurrent cases and 100% of recurrent cases, and showed osteoarthritis in 22% and 27% of nonrecurrent and recurrent cases, respectively. Ultrasound was used rarely, with the primary finding being a solid mass. US did not consistently identify involvement of other structures but did rule out ganglion cysts. MRI imaging was used some in both nonrecurrent (35%) and recurrent (50%) cases. MRI results showed periarticular soft tissue masses along tendon sheaths and frequently identified joint/collateral involvement. During the marginal excision, the structures encountered included the joints, the bone, the neurovascular bundle, and the flexor/extensor tendons (Table 3). Table 3Summary of Imaging and Surgical FindingsVariableNonrecurrentRecurrentDiffOR95% CI‡P ValueSignificant?Near or in joint58.7%81.8%+23.13.160.63–15.85.1900NoOA22.2%27.3%+5.11.310.31–5.62.7100NoOn or in bone47.6%100%+52.425.26∗1.43–447.18.0008YesN-V bundle25.4%63.6%+38.25.141.33–19.89.0290YesFlexor23.8%45.5%+21.62.670.71–9.99.1500NoExtensor31.7%36.4%+4.61.230.32–4.68.7400NoSatellite†0%18.2%+18.233.42∗1.49–750.86.0200Preliminary†N-V bundle, neurovascular bundle.∗Haldane–Anscombe corrected odds ratio (0.5 added to each cell because of zero counts).†Based on only two cases; insufficient sample to draw reliable conclusions about satellite lesions as a predictor of recurrence.‡The 95% CI was calculated using the Woolf logit method. Summary of Imaging and Surgical Findings N-V bundle, neurovascular bundle. Haldane–Anscombe corrected odds ratio (0.5 added to each cell because of zero counts). Based on only two cases; insufficient sample to draw reliable conclusions about satellite lesions as a predictor of recurrence. The 95% CI was calculated using the Woolf logit method. Surgery and imaging showed frequent involvement of joints with the DIP joint being the most common. The proximity of GCTTS to the joint showed recurrent tumors (81.8%) near or in joints with nonrecurrent (58.7%). The joint involvement trend was supported by odds ratio of 3.16 (95% CI 0.63–15.85) (Fig. 2). Photograph and schematic of GCTTS invading a ring finger DIP joint (arrow), terminal extensor tendon, collateral ligament, and flexor digitorum profundus tendon (FPL). The middle phalanx was most affected, followed by the distal and proximal phalanx (Fig. 3). Erosions were present in some recurrent cases (Fig. 4). The proximity of GCTTS to bone showed more recurrent tumors (100%) on or in bone than the nonrecurrent tumors (47.6%). This difference was statistically significant (P = .0008) and the strongest predictor of recurrence (OR 25.26, 95% CI 1.43–447.18). Bone involvement demonstrated high sensitivity (100%) for recurrence but low specificity (52.4%). Of 41 total patients with bone involvement, 30 (73.2%) did not experience recurrence, indicating that bone involvement was a necessary but not sufficient condition for recurrence in this series. Photograph of a large chronic GCTTS involving the radial neurovascular bundle, flexor tendon, and extensor tendon as well as compressing and flattening the middle phalanx. Radiograph of GCTTS of the left ring finger causing erosion of the radial cortex of the middle phalanx. Although neurologic signs were rare, involvement of the neurovascular bundle was not (Fig. 5), and was the second strongest significant (P = .0290) indicator of recurrence. Nonrecurrent tumors involved the bundle in 25%, whereas 64% of the recurrent tumors involved the bundle (OR 5.14, 95% CI 1.33–19.89). Photograph of GCTTS on the right index finger over middle phalanx (insert arrow). Note digital nerve (arrow at probe) adherent to the pseudocapsule of the tumor. Involvement of flexor tendons in nonrecurrent cases (24%) and recurrent cases (46%) was not significant (P = .1500), but the odds ratio (2.67, 95% CI 0.71–9.99) supported a trend for recurrence (Fig. 6). Involvement of extensor tendons was nearly equal in nonrecurrent (32%) and recurrent (36%) cases (OR 1.23, 95% CI 0.32–4.68). Likewise, there was no meaningful association of osteoarthritis (22% in nonrecurrent vs 27% in recurrent; OR 1.31, 95% CI 0.31–5.62). At surgery, an incomplete pseudocapsule was universal in both cohorts. Photograph of GCTTS attached to the flexor sheath and involving the flexor tendons. There were two satellite lesions in the recurrent group (P = .0200; OR 33.42, 95% CI 1.49–750.86). However, with only two cases, this sample size is insufficient to draw reliable conclusions about satellite lesions as a predictor of recurrence, and this observation should be considered hypothesis-generating only (Fig. 7). Photograph of primary GCTTS with distal smaller satellite GCTTS. All tumors were confirmed by histology and gross pathologic descriptions reported yellow-tan, soft to firm, or sometimes rubbery nodules. Mean volume did not differ (1.33 cm3 in nonrecurrent vs 1.29 cm3 in recurrent). Surgical complications were minor, self-limited, and included postoperative sensory changes. Minor complications occurred similarly between nonrecurrent (16%) and recurrent (18%) cases. Discussion This retrospective study examined indicators of recurrence in 74 patients with GCTTS treated at a single academic center over 23 years. All surgeries were performed by fellowship-trained hand surgeons using marginal excision with surgical adjuncts including extensile incisions, loupe magnification, tourniquet control, and meticulous secondary survey of the tumor bed (Fig. 8). The overall recurrence rate was 15%. This value is below the average rate of 28.5% reported in the review by Lanzinger and Bindra and within the literature range of 4% to 56%.5,10,11,15,18,20,25 Photograph of surgical bed ready for secondary survey following marginal excision of GCTTS. Labeled structures include the digital nerve (1), flexor tendon sheath (2), and digital artery (3). In addition, note the ruler with two red lines. The diameter of a giant cell ranges from 40 to 120 μm. If giant cells were placed on a line between the two red markers, 50 small or 17 large giant cells could be attached to the digital nerve in this tiny space. Therefore, even the most thorough secondary survey with 3.5 loupe magnification has a high potential to leave behind tumor cells.30 Notably, two significant and clinically robust predictors of recurrence were identified. First, bone involvement was present in 100% of recurrent cases compared to 47.6% of nonrecurrent cases, representing the strongest predictor in our study. This corroborates several earlier investigations6,11,14,15,25 and is consistent with the recent findings of Cengiz et al,27 who identified bone invasion as a significant risk factor for both surgical margin positivity and recurrence in 44 patients with localized hand TGCTs. Second, neurovascular bundle involvement was significantly more common in recurrent cases (63.6%) than nonrecurrent cases (25.4%), also supporting prior literature11,14 and confirmed by Cengiz et al27 as a significant predictor of margin positivity. Additionally, satellite lesions were identified in only two patients (2/74), both in the recurrent group; however, this sample size is too small to conclude that they are a significant predictor of recurrence. Although the literature has reported satellite lesion rates as high as 17% and suggested an association with recurrence,7,11,14, 15, 16,18,22,23,25 our finding should be viewed as indicating greater vigilance for satellite lesions during surgery rather than as evidence of a significant relationship. The finding that bone involvement was present in all 11 recurrent cases and 30 of 63 nonrecurrent cases warrants careful interpretation. Bone involvement was a necessary but not sufficient condition for recurrence in this series. This high nonrecurrence rate among bone-involved patients likely reflects the effectiveness of our standardized surgical protocol, which included aggressive curettage of involved bone as a routine adjunct to marginal excision. Under tourniquet control and loupe magnification, meticulous curettage of the bony bed was performed in all cases with bone involvement, followed by a systematic secondary survey to identify residual tumor. The ability to prevent recurrence in nearly three-quarters of bone-involved cases suggests that aggressive curettage can substantially mitigate the recurrence risk posed by bone involvement. This finding therefore carries a dual clinical message: bone involvement identifies patients at elevated risk who warrant heightened surveillance and counseling, but this risk can be meaningfully reduced using meticulous surgical techniques with thorough bone curettage. The strong association between bone involvement and recurrence aligns with the understanding that complete excision of tumors extended into bone is technically challenging. Even with meticulous curettage,5,14,15 residual tumor cells may persist, as evidenced by the 26.8% of bone-involved patients who did recur despite aggressive treatment. Cengiz et al27 further demonstrated that bone invasion and interphalangeal joint proximity were the strongest preoperative predictors of positive surgical margins, reinforcing the importance of recognizing these features during surgical planning. Neurovascular involvement predicting recurrence reflects the surgical dilemma inherent in treating these tumors. Dissecting the tumor from the neurovascular bundle may require opening the pseudocapsule, potentially seeding the surgical bed with residual tumor cells or leaving tumor cells adherent to nerve or artery.5,8,14,15,21,22 This underscores the importance of preoperative MRI to identify bundle involvement. Several additional findings demonstrated trends toward recurrence. Joint involvement showed more recurrent tumors (81.8%) compared to nonrecurrent tumors (58.7%) (OR 3.16, 95% CI 0.63–15.85), consistent with prior reports of DIP joint involvement as a risk factor.11,12,14, 15, 16,25,31 Flexor tendon involvement also trended toward recurrence (46% vs 24%; OR 2.67, 95% CI 0.71–9.99), whereas extensor tendon involvement showed no meaningful association (36% vs 32%; OR 1.23, 95% CI 0.32–4.68). Consistent with the previous literature, several characteristics did not predict recurrence, including pseudocapsule integrity, rheumatoid arthritis, osteoarthritis, tumor cellularity, histology and mitotic activity, size, duration of symptoms, and women.6,8,11,12,14,15,18,19,25,26,32 However, women constituted a larger proportion of GCTTS cases (69% overall, 82% in the recurrent group), supporting observations that GCTTS may be more aggressive in women. This study has several limitations. First, as a retrospective study, data were collected from article and electronic records as well as phone calls, resulting in variable completeness and accuracy. In addition, the small sample size limits study power. Notably, the wide confidence intervals observed for all ORs, particularly for bone involvement and satellite lesions, reflect the limited precision of these estimates because of the small number of recurrence events. Moreover, the satellite lesion finding is based on only two cases, which is insufficient to infer a significant association. Finally, imaging varied, with MRI performed in only 35% of nonrecurrent and 50% of recurrent cases. Given the superiority of MRI in identifying satellite lesions, bone involvement, and tumor extensions,3,12,14,15,20,22, 23, 24 inconsistent imaging may have masked their association with recurrence. As such, the study findings should be interpreted as hypothesis-generating rather than definitive and will necessitate confirmation in larger studies. The low overall recurrence rate (15%) in our series compared to the literature average (28.5%) likely reflects the standardized surgical approach employed, including extensile incisions, loupe magnification, tourniquet control, preservation of the pseudocapsule when possible, joint exploration, secondary survey of the surgical bed, and identification of satellite lesions.5,14,15,21 These results support recommendations that GCTTS require more than simple excision; they demand meticulous microsurgical dissection. Regarding satellite lesions, although our observation of their exclusive occurrence in the recurrent group is consistent with the direction of prior reports,7,10,11,15,19,26 the extremely small sample size precludes any definitive conclusions about their predictive value. Nevertheless, this finding indicates greater vigilance: surgeons should carefully inspect for satellite lesions during secondary survey, noting the subtle color differences between tumor and fat.5,10,14,15 Complete surgical excision represents the best prevention of recurrence14,26; however, this goal is not always achievable. Given the relatively short interval between primary surgery and recurrence in most cases, it is unlikely that these arose from de novo chromosomal translocations; rather, recurrent tumors likely arise from residual neoplastic cells or unrecognized satellite lesions.33,34 This understanding suggests three general approaches to improving recurrence management. First, biomarkers such as Ki-67 index, mitotic activity, and CSF1 expression may help identify patients at higher risk for recurrence who warrant more vigilant surveillance. Bedir et al35 demonstrated that the Ki-67 index was significantly higher in recurrent cases compared with mitotic activity, which was similarly elevated in recurrent tumors. Second, new intraoperative imaging technology could improve the secondary survey and minimize the presences of residual tumor cells. Intraoperative ultrasound or emerging modalities such as handheld optical coherence tomography, which has been applied to articular cartilage,36 might enable real-time identification of residual tumor deposits or satellite lesions. Third, systemic agents targeting the CSF1 pathway have shown efficacy in GCTTS. The neoplastic cells harboring CSF1 translocations represent only 2% to 16% of tumor mass but drive disease through a “landscape effect,” secreting CSF1 that recruits macrophages, osteoclast-like giant cells, and other inflammatory cells that constitute the tumor bulk.23,33,34 Pexidartinib (PLX3397), a CSF1R inhibitor, achieved tumor response in 52% of patients with GCTTS in a phase 1 trial.37 More recently, the phase 3 MOTION trial demonstrated that vimseltinib, a highly selective CSF1R inhibitor, achieved significant tumor response compared with placebo in patients with TGCT, leading to US Food and Drug Administration approval for symptomatic TGCT where surgery would cause worsening functional limitation or severe morbidity.38 However, the risk–benefit profile of such agents remains debatable given the benign nature of these lesions and adverse effects, though vimseltinib has demonstrated an improved hepatic safety profile compared with pexidartinib.2,3,15,23,37,38 The external validity of these findings should be considered in the context of several factors. Our patient population, with a mean age of 50 years, 69% women, predominant involvement of radial digits and DIP joint, is consistent with the typical demographic and anatomic distribution reported in the literature supporting the representativeness of our sample.5,6,8,11, 12, 13, 14, 15,17 However, generalization of our recurrence rate (15%) to other settings requires caution. This rate was achieved at an academic medical center by fellowship-trained hand surgeons using a standardized approach with multiple surgical adjuncts. The prior literature has suggested that surgeon experience and anesthesia type may influence outcomes.11 Future multi-institutional studies with larger sample sizes and standardized MRI protocols would strengthen evidence regarding recurrence predictors. Investigation of histological parameters, such as mitotic activity and Ki-67 proliferation index,35 as well as characterization of molecular markers related to CSF1 expression and chromosomal translocations is also recommended.23,33,34,39 As recommended by the recent international consensus on TGCT management, a multidisciplinary approach integrating surgical expertise, advanced imaging, and consideration of systemic therapies for refractory cases represents the optimal strategy for managing these tumors.4 Finally, evaluation of intraoperative imaging modalities to improve detection of residual tumor and satellite lesions also merits investigation. Until then, meticulous surgical technique with attention to the risk factors identified in this and prior studies remains the cornerstone of preventing recurrence in GCTTS. Patients with these high-risk factors of recurrence should also be counseled about recurrence and followed at least 5 years. Conflicts of Interest The authors have no relevant conflicts to disclose. References